LAVAL, QC, Feb. 11 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX;TSX: NRM) announces today that on Wednesday, February 13, 2008, Dr. FrancescoBellini, Neurochem's Chairman, President and Chief Executive Officer, and Mr.Gary Schmid, Chief Executive Officer of the new nutraceutical business, willpresent Neurochem's strategy at the 2008 BIO CEO & Investor Conference to beheld at the Waldorf-Astoria, in New York (NY). The presentation will takeplace at 11:00 A.M. EST, in the West Foyer room.
The live Web cast of Neurochem's presentation (audio and visual) can beaccessed athttp://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NRMX&item_id=17. Areplay of the presentation will begin one (1) hour after the actualpresentation time, and will be available until February 20, 2008. Pleaseaccess the Web cast approximately 15 minutes before the presentation isscheduled to begin.
Neurochem Inc. is a global health company focused on the research,development and commercialization of products to provide innovative healthsolutions to address critical unmet medical needs.
To Contact Neurochem
For additional information on Neurochem and its drug development programs,please call the North American toll-free number 1-877-680-4500 or visit ourWeb Site at www.neurochem.com.
Certain statements contained in this news release, other than statementsof fact that are independently verifiable at the date hereof, may constituteforward-looking statements. Such statements, based as they are on the currentexpectations of management, inherently involve numerous risks anduncertainties, known and unknown, many of which are beyond Neurochem Inc.'scontrol. Such risks include but are not limited to: the impact of generaleconomic conditions, general conditions in the pharmaceutical and/ornutraceutical industry, changes in the regulatory environment in thejurisdictions in which the Neurochem group does business, stock marketvolatility, fluctuations in costs, and changes to the competitive environmentdue to consolidation, that actual results may vary once the final andquality-controlled verification of data and analyses has been completed, aswell as other risks disclosed in public filings of Neurochem Inc.Consequently, actual future results may differ materially from the anticipatedresults expressed in the forward-looking statements. The reader should notplace undue reliance, if any, on any forward-looking statements included inthis news release. These statements speak only as of the date made andNeurochem Inc. is under no obligation and disavows any intention to update orrevise such statements as a result of any event, circumstances or otherwise,unless required by applicable legislation or regulation. Please see the AnnualInformation Form of Neurochem Inc. for further risk factors that might affectthe Neurochem group and its business.For further information, please contact: Lise Hebert, PhD, Vice President, Corporate Communications Tel: (450) 680-4572 firstname.lastname@example.org
SOURCE NEUROCHEM INC.